Form 4: Evolus CMO Sells Shares for Tax Obligations

Evolus, Inc.'s Chief Medical Officer, Rui Avelar, sold 2,261 shares of common stock on December 22, 2025, to cover tax withholding obligations related to restricted stock unit vesting.

Summary

• Rui Avelar, Chief Medical Officer & Head of Research and Development at Evolus, Inc., reported a sale of common stock.
• The transaction involved the disposition of 2,261 shares of Evolus common stock.
• The shares were sold at a price of $7.1507 per share.
• The sale occurred on December 22, 2025.
• Following this transaction, Rui Avelar beneficially owns 356,821 shares of Evolus common stock directly.
• The sale was executed under a Rule 10b5-1 trading plan.
• The purpose of the sale was to cover tax withholding obligations associated with the vesting of restricted stock units.

Sentiment

Score: 5

Explanation: The filing reports a routine insider sale for tax purposes under a pre-arranged 10b5-1 plan, which is a neutral event. It does not indicate any significant positive or negative sentiment regarding the company's performance or outlook.

Positives

• The sale was pre-planned under a Rule 10b5-1 trading plan, indicating a structured approach to managing equity compensation rather than an opportunistic sale.

Negatives

• A reduction in direct insider ownership, even for tax purposes, can sometimes be perceived negatively by investors, though it is a common practice.

Future Outlook

No specific future outlook or guidance is provided in this Form 4 filing.

Management Comments

• The sales reported on this Form 4 were effected pursuant to a Rule 10b5-1 trading plan adopted by the Reporting Person and represent shares required to be sold by the Reporting Person to cover tax withholding obligations in connection with the vesting of certain restricted stock units.

Industry Context

This is a routine insider transaction for tax purposes, common across all industries when executives receive equity compensation. It does not provide specific insights into broader biotechnology or aesthetics industry trends.

Comparison to Industry Standards

• This is a standard practice for executives to sell shares to cover tax obligations upon restricted stock unit (RSU) vesting. Many companies in the biotechnology and pharmaceutical sectors, such as AbbVie or Allergan (now part of AbbVie), have executives who engage in similar tax-related sales of equity awards.
• For example, an executive at a comparable company like Revance Therapeutics (RVNC) or Merz Aesthetics would likely execute similar transactions when their restricted stock units vest, making this transaction consistent with industry norms.

Related Party Transactions

• The reported transaction involves an insider (Chief Medical Officer) selling company stock, which is a related party transaction. However, it is a standard event for covering tax obligations related to equity compensation.

Stakeholder Impact

• Shareholders: A minor reduction in insider ownership, but for a common and expected reason (tax withholding). The impact is generally minimal as it is not a discretionary sale.
• Employees: No direct impact on employees.
• Customers/Suppliers/Creditors: No direct impact on these stakeholders.

Key Dates

Recommendation

This Form 4 reports a routine, non-discretionary sale of shares by an executive to cover tax obligations upon the vesting of restricted stock units, executed under a pre-arranged 10b5-1 plan. Such transactions are common and do not typically reflect a change in management's confidence in the company's future or provide new material information that would warrant a change in investment recommendation. Therefore, a 'hold' recommendation is appropriate as this filing does not present new fundamental drivers for a 'buy' or 'sell' decision.

Keywords

Evolus, EOLS, Rui Avelar, Insider Trading, Form 4, Stock Sale, Tax Withholding, Restricted Stock Units, 10b5-1 Plan, Biotechnology, Aesthetics